ATE387911T1 - Katecholderivate zur behandlung von krebs - Google Patents

Katecholderivate zur behandlung von krebs

Info

Publication number
ATE387911T1
ATE387911T1 AT04777151T AT04777151T ATE387911T1 AT E387911 T1 ATE387911 T1 AT E387911T1 AT 04777151 T AT04777151 T AT 04777151T AT 04777151 T AT04777151 T AT 04777151T AT E387911 T1 ATE387911 T1 AT E387911T1
Authority
AT
Austria
Prior art keywords
alkyl
medicament
cancer
catechole
derivatives
Prior art date
Application number
AT04777151T
Other languages
English (en)
Inventor
John C Reed
Maurizio Pellecchia
Original Assignee
Burnham Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burnham Inst filed Critical Burnham Inst
Application granted granted Critical
Publication of ATE387911T1 publication Critical patent/ATE387911T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04777151T 2003-06-25 2004-06-25 Katecholderivate zur behandlung von krebs ATE387911T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48288603P 2003-06-25 2003-06-25

Publications (1)

Publication Number Publication Date
ATE387911T1 true ATE387911T1 (de) 2008-03-15

Family

ID=34102647

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08003839T ATE478663T1 (de) 2003-06-25 2004-06-25 Analoga von apogossypol zur verwendung in der behandlung von krebs
AT04777151T ATE387911T1 (de) 2003-06-25 2004-06-25 Katecholderivate zur behandlung von krebs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08003839T ATE478663T1 (de) 2003-06-25 2004-06-25 Analoga von apogossypol zur verwendung in der behandlung von krebs

Country Status (13)

Country Link
US (3) US7812058B2 (de)
EP (2) EP1653943B3 (de)
JP (2) JP2007524633A (de)
AT (2) ATE478663T1 (de)
AU (1) AU2004258867B2 (de)
CA (1) CA2529507C (de)
DE (2) DE602004012279T3 (de)
DK (1) DK1653943T4 (de)
ES (2) ES2351581T3 (de)
PL (1) PL1653943T6 (de)
PT (1) PT1653943E (de)
SI (1) SI1653943T1 (de)
WO (1) WO2005009434A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432304B2 (en) 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
WO2003038060A2 (en) * 2001-11-01 2003-05-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at bcl-2
JP2007524633A (ja) 2003-06-25 2007-08-30 ザ バーナム インスティチュート 癌細胞におけるアポトーシスの誘導のための化合物および方法
EP1732529A4 (de) * 2004-03-25 2009-02-25 Univ Michigan Gossypol kokristalle und ihre verwendung
US20060144723A1 (en) * 2004-11-02 2006-07-06 Mary Fuller Device for securing valuables
EP2197273B1 (de) * 2007-10-01 2014-09-24 Ascenta Therapeutics, Inc. Verfahren zur herstellung von r-gossypol-l-phenylalaninol-dienamin
US8039668B2 (en) 2008-10-17 2011-10-18 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
EP2205088B1 (de) * 2007-10-19 2018-02-21 Burnham Institute for Medical Research Auf naphthalin basierende hemmer von anti-apoptotischen proteinen
FR2924712B1 (fr) 2007-12-06 2012-12-21 Univ Maine Derives du gossypol et de l'apogossypol, leurs preparations et leurs applications
GB0725077D0 (en) * 2007-12-21 2008-01-30 Univ Murcia Antifolate com[ounds for the treatment of melanoma
WO2009126172A1 (en) * 2008-04-11 2009-10-15 The Trustees Of Columbia University In The City Of New York Resistance to polyphenon e due to increased bcl-2 expression
CA2733930A1 (en) * 2008-08-14 2010-02-18 The Uab Research Foundation Anti-arrhythmia agents, methods of their use, methods of their identification, and kits therefore
US8487131B2 (en) 2009-04-15 2013-07-16 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
WO2011017096A2 (en) * 2009-08-04 2011-02-10 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
AU2010303324A1 (en) 2009-10-08 2012-04-05 Sanford-Burnham Medical Research Institute Apogossypolone derivatives as anticancer agents
WO2014127191A1 (en) 2013-02-15 2014-08-21 The Regents Of The University Of Michigan Compositions and methods relating to hindering dot1l recruitment by mll-fusion proteins
US9180226B1 (en) 2014-08-07 2015-11-10 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US9655998B2 (en) 2014-08-07 2017-05-23 Cook Medical Technologies Llc Encapsulated drug compositions and methods of use thereof
US11241520B2 (en) 2014-08-07 2022-02-08 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
JP2018512450A (ja) * 2015-03-19 2018-05-17 ウェンディ アン エプスタインＥＰＳＴＥＩＮ， Ｗｅｎｄｙ Ａｎｎｅ 女性の性的障害を治療するための化合物及び剤型
RU2654711C1 (ru) * 2017-07-10 2018-05-22 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, обладающее апоптоз-индуцирующей активностью
CN115281419B (zh) * 2018-04-20 2024-11-05 耐克创新有限合伙公司 带有板和中间流体填充囊的鞋底结构及其制造方法
CN110128290B (zh) * 2019-05-10 2022-04-29 江苏耐雀生物工程技术有限公司 红倍酚苯甲酰肼衍生物、中间体、制备方法及其应用
CA3155694A1 (en) * 2019-09-24 2021-04-01 Genetec Inc. Intermediary device for daisy chain and tree configuration in hybrid data/power connection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
JPH1036260A (ja) * 1996-07-18 1998-02-10 Mitsui Norin Kk 抗ガン剤の効力増強方法
US5804567A (en) * 1996-07-18 1998-09-08 Cancer Institute (Hospital), Chinese Academy Of Medical Sciences Method of increasing the effectiveness of anti-metabolites
US6428818B1 (en) 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
US6608107B2 (en) * 2000-12-15 2003-08-19 Wackvom Limited Methods and compositions to treat conditions associated with neovascularization
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
WO2002097053A2 (en) * 2001-05-30 2002-12-05 The Regents Of The University Of Michigan Small molecule antagonists of bcl2 family proteins
JP2007524633A (ja) * 2003-06-25 2007-08-30 ザ バーナム インスティチュート 癌細胞におけるアポトーシスの誘導のための化合物および方法

Also Published As

Publication number Publication date
ATE478663T1 (de) 2010-09-15
US20120269901A1 (en) 2012-10-25
DE602004012279T3 (de) 2010-07-15
AU2004258867B2 (en) 2010-02-18
PL1653943T3 (pl) 2008-09-30
EP1653943B1 (de) 2008-03-05
EP1938816B1 (de) 2010-08-25
EP1938816A2 (de) 2008-07-02
EP1653943B3 (de) 2008-07-30
DE602004012279T2 (de) 2009-07-16
DE602004028880D1 (de) 2010-10-07
DE602004012279T9 (de) 2010-01-28
WO2005009434A2 (en) 2005-02-03
US8367644B2 (en) 2013-02-05
CA2529507A1 (en) 2005-02-03
DK1653943T3 (da) 2008-06-23
US20050027000A1 (en) 2005-02-03
PL1653943T6 (pl) 2009-02-27
AU2004258867A1 (en) 2005-02-03
JP2007524633A (ja) 2007-08-30
ES2351581T3 (es) 2011-02-08
EP1938816A3 (de) 2008-08-06
EP1653943A2 (de) 2006-05-10
US20110111057A1 (en) 2011-05-12
SI1653943T1 (sl) 2008-08-31
CA2529507C (en) 2011-08-09
ES2303096T3 (es) 2008-08-01
DE602004012279D1 (de) 2008-04-17
PT1653943E (pt) 2008-05-23
JP2012025767A (ja) 2012-02-09
US7812058B2 (en) 2010-10-12
WO2005009434A3 (en) 2005-06-09
DK1653943T4 (da) 2008-12-01
ES2303096T7 (es) 2009-06-18

Similar Documents

Publication Publication Date Title
ATE387911T1 (de) Katecholderivate zur behandlung von krebs
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ATE358668T1 (de) Drogen zur behandlung maligner tumoren
GB0318447D0 (en) Therapeutic agents
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
TNSN04065A1 (en) Treatment of acute myeloid leukemia with indolinone compounds
AR050045A1 (es) Derivados de pirrolo[3,4-c]pirazol activos como inhibidores de quinasa, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden
NO20004162D0 (no) Antitumor agens
MXPA05010020A (es) Derivados de oxamida.
ZA200901921B (en) Pyrazolopyrimidine derivative
EA200701780A1 (ru) Противоопухолевое средство
BR0311136A (pt) composto ou um sal, enanciÈmero, diaestereÈmero ou éster hidrolisável in vivo ou mistura dos mesmos farmaceuticamente aceitável, composição, e, método para inibir a atividade de fator letal (lf) liberado de bactérias em um mamìfero
TW200510384A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
SE0201837D0 (sv) Chemical compounds
WO2002074756A3 (de) Urokinase-inhibitoren
SE0004827D0 (sv) Therapeutic compounds
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
BR0308911A (pt) Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto
TW200640464A (en) Pharmaceutical composition comprising phenoxazinium compounds as an active ingredient
SE0103272D0 (sv) Chemical compounds
TW200503714A (en) Pde9 inhibitors for treating type 2 diabetes, metabolic syndrome, and cardiovascular disease
MY139960A (en) Treatment of acute myeloid leukemia with indolinone compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1653943

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
UEP Publication of translation of european patent specification

Ref document number: 1653943

Country of ref document: EP